Scientist II, Investigative Toxicology, Drug Safety Research and Evaluation, Takeda Pharmaceuticals, Cambridge, MA
Piyush Bajaj got his PhD from the University of Illinois Urbana Champaign. Dr. Bajaj then did a postdoc at Los Alamos national lab (LANL) developing organs-on-a-chip which could be used for both efficacy and safety assessment. After his postdoc at LANL, Dr. Bajaj moved to Pfizer where he developed/validated protocols for generating human pluripotent stem cell-derived three-dimensional (3D) kidney organoids and was involved in de-risking of potential target organ toxicities using physiologically relevant in vitro models. Dr. Bajaj is now a part of Takeda’s investigative toxicology group where he co-leads liver and kidney de-risking strategies which are applied for proactive management of potential safety liabilities of compounds in the discovery stages.